Navigation Links
InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference
Date:9/4/2008

FORT COLLINS, Colo., Sept. 4 /PRNewswire/ -- InVitria (http://www.invitria.com), a leading global supplier of animal free products that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry, announced its Sponsorship of Cambridge Healthtech Institute's 4th Annual "Optimizing Cell Culture Development" Conference on September 15-16 in Boston, Massachusetts. (http://www.healthtech.com/ocb/overview.aspx?c=562)

InVitria will be an exhibitor at the conference, which will feature notable speakers from research and development institutes and the biotech industry. The meeting sessions focus on cell line development, cell engineering, upstream processing and scale-up & manufacturing of products derived from cell culture.

"InVitria is very pleased to serve as one of the corporate sponsors for this event for the cell culture industry," said Scott Deeter, InVitria's president. "We feel this is a tremendous venue to build awareness of how InVitria's animal free products available for use in cell culture media help improve productivity, safety and time to market for our customers."

"InVitria's Cellastim and Lacromin not only replace bovine or human sources of albumin or transferrin, but they also provide improved productivity and better consistency," said Ray Tritch, InVitria's Account Manager - Eastern United States. "I am looking forward to sharing our successful results using these cell culture ingredients to optimize performance," Tritch said.

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim -- Cellastim is an albumin used to replace bovine albumin and human albumin as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity by up to 50% when compared with other forms of albumin. Cellastim also has been an effective component in stem cell media and primary cell media. (see http://www.Cellastim.com )

-- Lacromin -- Lacromin has been shown to replace bovine transferrin and human transferrin in cell culture media. In addition, Lacromin is a strong growth promotant as a cell culture ingredient in mammalian cell culture media. (see http://www.Lacromin.com )

-- Lysobac -- Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields. (see http://www.Lysobac.com )

For more information about the InVitria line of products, please e-mail info@invitria.com or call 1-800-916-8311.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
2. InVitria Expands Sales Team
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment
5. BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008
6. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
7. Baxa Announces Colorado BioScience Association Sponsorship
8. Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer
9. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
10. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
11. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
(Date:12/2/2016)... NC (PRWEB) , ... December 01, 2016 , ... ... US Computational Science Symposium (CSS) and the popularity of US Single Day Events ... take place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical ...
(Date:12/2/2016)... Boston, MA (PRWEB) , ... December 02, 2016 , ... ... of Light Event on December 3rd, 2016. The event, which is held on ... NTI’s work with helping Americans with Disabilities back into the workplace. Suitable Technologies is ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
Breaking Biology Technology:
(Date:11/29/2016)... -- Nearly one billion matches per second with DERMALOG,s high-speed ... ... DERMALOG is Germany's largest Multi-Biometric supplier: ... (PRNewsFoto/DERMALOG Identification Systems) ... is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):